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ABSTRACT
We compared the outcomes of 141 consecutive patients who received allogeneic transplantation with either
myeloablative (MA) or nonmyeloablative/reduced intensity (NMA) conditioning for non-Hodgkin and Hodgkin
lymphoma at the University of Minnesota. All patients were transplanted between 1997 and 2004. NMA trans-
plant recipients were older and received umbilical cord blood grafts more frequently (MA: 6 [9%]; NMA: 33
[43%], P\ .001). NMA patients had more advanced disease and 30 (39%) patients had undergone prior autol-
ogous transplantation. The 4-year overall survival (OS) (MA: 46% versus NMA: 49%; p 5 .34) and the 3-year
progression-free survival (PFS) (MA: 44% versus NMA: 31%; P 5 0.82) were similar after MA or NMA condi-
tioning. However, MA conditioning resulted in significantly higher 1-year treatment-related mortality (TRM)
(MA: 43% versus NMA: 17%; P\ .01) but a lower risk of relapse at 3 years (MA: 11% versus NMA: 36%; P\
.01). We conclude that similar transplant outcomes are achieved after allogeneic hematopoietic stem cell trans-
plantation using MA conditioning in younger patients and NMA conditioning in older patients or those with
prior autologous transplantation not eligible for MA conditioning. Modifications to refine patient assignment
to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed.
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Lymphoma, particularly non-Hodgkin lymphoma
(NHL), is progressively increasing in incidence [1].
Since 1995, autologous hematopoietic stem cell trans-
plantation (AuHCT) has been the preferred manage-
ment for diffuse large cell NHL in second remission
[2]. The application of AuHCT to other lymphoma
subtypes and prognostic indications defining the opti-
mal timing of transplant continue to evolve. Despite
this, nearly 20,000 persons in the United States are
estimated to die from lymphoma in 2007, whereas
only approximately 2500 autologous and allogeneic
transplants per year are performed for lymphoma [1,3].538Relapse remains the most common cause of death
after AuHCT for lymphoma [3]. Allogeneic transplant
(AlloHCT) offers disease control from a graft-versus-
lymphoma (GVL) effect in addition to control from
the conditioning regimen, but is associated with higher
treatment-related complications [4-7]. Continued
improvements in the outcomes of AlloHCT and newer
conditioning regimens have led to greater exploration
of AlloHCT for patients with advanced lymphoma.
Limited yet inconclusive data have been published
comparing myeloablative (MA) versus nonmyeloabla-
tive (NMA) regimens for lymphoma management
[8-11]. To better address the comparative safety and
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secutive patients with either NHL or Hodgkin lym-
phoma (HL) treated with AlloHCT in our institution.
METHODS
The University of Minnesota maintains a database
of all consecutive patients enrolled in institutional re-
view board-approved clinical transplantation trials.
Retrospective review of this database identified all pa-
tients with either NHL or HL that were treated with
AlloHCT between January 1997 and December 2004.
Eligibility
All patients had chemotherapy-responsive disease
defined as achieving at least a minimal response to
the preceding salvage regimen. Indications for NMA
conditioning included at least 1 of the following: prior
AuHCT; older age (.55 years for related donor or
.45 years for an unrelated donor including umbilical
cord blood); extensive prior therapy defined as .12
months of alkylator therapy or 6 months of alkylator
therapy with extensive radiation; impaired cardiac or
pulmonary function (ejection fraction $35% and/or
corrected DLCO $30%, respectively); or recent fun-
gal infection controlled with a minimum of 30 days of
therapy. To be eligible for MA conditioning, patients
were required to have an ejection fraction $45% and
a corrected DLCO $50% and not have any of the
other criteria indicating the need for NMA condition-
ing. Donors were either related donors (RD) (6 of 6 or
5 of 6 HLA match), adult volunteer unrelated donors
(URD) (7-8 of 8 HLA match), or unrelated umbilical
cord blood (UCB) units (4-6 of 6 HLA match). UCB
transplants were either single or double units as previ-
ously described [12,13]. Patients seropositive for
human immunodeficiency virus were excluded.
Treatment
MA conditioning (Table 1) consisted of intrave-
nous (i.v.) cyclophosphamide (Cy) 120 mg/kg divided
over 2 days plus either fractionated total-body irradia-
tion (TBI) 1320 cGy divided twice daily over 4 days; or
oral busulfan (Bu) 16 mg/kg divided every 6 hours over
4 days; or, for UCB transplants, TBI 1320 cGy plus i.v.
fludarabine (Flu) 75 mg/m2 divided over 3 days. NMA
conditioning consisted of a single fraction of TBI
200cGy along with either i.v. Flu 200 mg/m2 divided
over 5 days plus i.v. Cy 50 mg/kg as a single dose; or
i.v. Flu 200 mg/m2 plus oral Bu 8 mg/kg divided every
6 hours over 2 days; or i.v. Cladrabine 50 mg/m2 plus
oral Bu 8 mg/kg. Equine antithymocyte globulin (15
mg/kg i.v. every 12 hours for 6 doses) was added to
NMA conditioning if patients had not received any
combination chemotherapy in the preceding 3 months
for UCB (n5 2) or preceding 6 months (n5 2) for sib-
ling transplants. Graft-versus-host disease (GVHD)prophylaxis was i.v. or oral cyclosporine (CSA) tar-
geted to 200-400 ng/mL and either i.v. Methotrexate
15 mg/m2 on day 11 and 10 mg/m2 on days 13, 16,
and111 forMA conditioning; or i.v. or oralMycophe-
nylate mofetil (MMF) 1000 mg every 12 hours until
day 130 after NMA conditioning or for recipients of
UCB transplants regardless of conditioning intensity.
All patients received antibacterial, antiviral, and anti-
fungal prophylaxis and blood product support per in-
stitutional guidelines. All patients received filgrastim
posttransplant until achieving an absolute neutrophil
count (ANC) $2.5  109/L for 2 days.
Statistical Analysis
Patient and transplant characteristics by type of
conditioning were analyzed using the chi-square test
for categoric data and the Wilcoxon Rank-Sum test
for continuous data. The primary study endpoint was
overall survival (OS). Secondary endpoints were pro-
gression-free survival (PFS), treatment-relatedmortal-
ity (TRM), relapse or disease progression, acute
GVHD (aGVHD) grade II-IV and grade III-IV,
chronic GVHD (cGVHD), neutrophil engraftment,
and platelet engraftment.
Event time for neutrophil engraftment was the
date of transplantation to the first of 3 consecutive
days with an ANC above 0.5  109/L. The cumulative
incidence of neutrophil engraftment was calculated by
treating patients without an ANC.0.5 109/L at day
42 or with autologous marrow reconstitution as pri-
mary graft failures. Time to platelet engraftment was
defined as the first day with a platelet count .20 
109/L without transfusions for the 7 following days.
Diagnosis of aGVHD and cGVHD was based on
standard clinical criteria with histopathologic con-
firmation where possible [14]. The cumulative inci-
dences of neutrophil and platelet engraftment,
aGVHD, and cGVHD and relapse were calculated
by treating deaths from other causes as competing risks
[15]. OS and PFS were estimated by the Kaplan-Meier
method [16]. PFS was defined at the time of last fol-
low-up for those patients that were alive without
disease relapse or progression. TRM was defined as
death without disease progression or relapse. Diagno-
ses of disease response and relapse or progression were
defined according to standard criteria for lymphoma
[17]. Event times were measured from the date of
transplantation to the event or the date of last contact.
Statistical comparisons of the time-to-event curves
were completed by the log-rank test or the Gray
method, where appropriate.
Proportional hazards regression modeling was
used for multiple regression analysis with Cox
regression and the Gray and Fine competing hazards
method as appropriate [18,19]. Variables considered
in the models included the main effect variable of
540 M. Tomblyn et al.Table 1. Patient Characteristics Compared by Conditioning Cohorts
Myeloablative Nonmyeloablative
N 5 65 N 5 76
N (%) N (%) P-value
Age, years—median (range) 42 (4-58) 48 (19-66) \.01
Gender, male 40 (62) 46 (61) NS
Disease
NHL* 62 (95) 53 (70) \.01
HL 3 (5) 23 (30)
Disease status at transplant
CR11 18 (28) 11 (14) NS
PR11 37 (57) 49 (64)
Minimally responsive disease 10 (15) 16 (21)
Prior autologous transplant
Yes 0 30 (39) \.01
No 65 (100) 46 (61)
Donor
Matched related 49 (75) 32 (42) \.01
Unrelated/mismatched related 10 (15) 11 (14)
Umbilical cord blood 6 (9) 33 (43)
Stem cell source
Bone marrow 5 (8) 8 (10) \.01
PBSC 54 (83) 35 (46)
Umbilical cord blood 6 (9) 33 (43)
Donor/recipient CMV serostatus
Both negative 21 (32) 40 (53) .02
Either positive 44 (68) 36 (47)
Conditioning regimen†
Cy120/TBI (1320 cGy) 49 (75)
Bu16/Cy120 12 (18)
Flu75/Cy120/TBI (1320 cGy) 4 (6)
Flu200/Cy50/TBI (200 cGy) 48 (64)
Flu200/Bu8/TBI (200 cGy) 21 (27)
Bu8/Clad50/TBI (200 cGy) 7 (9)
GVHD prophylaxis
CSA/Methotrexate 59 (91) 0 \.01
CSA/MMF 6 (9) 76 (100)
Year of transplant
1997-2000 31 (48) 10 (13) \.01
2001-2004 34 (52) 66 (87)
Time from diagnosis to transplant (month) 16 (3-106) 30 (8-247) \.01
GVHD indicates graft-versus-host disease; PBSC, peripheral blood stem cells; NHL, non-Hodgkin’s lymphoma; CR, complete remission; PR,
partial remission; CMV, cytomegalovirus; HL, Hodkin’s lymphoma; TBI, total-body irradiation.
*Mantle cell lymphoma (MA, n 5 13; NMA, n 5 7); indolent lymphomas including follicular and small lymphocytic lymphoma (MA, n 5 11;
NMA, n 5 24); diffuse large cell lymphoma (MA, n 5 7; NMA, n 5 11); T cell lymphomas (MA, n 5 8; NMA, n 5 6); and other lymphomas
including aggressive lymphomas such as transformed or Burkitt’s lymphomas (MA, n 5 23; NMA, n 5 5).
†Cy1205 cyclophosphamide 120mg/kg total dose; Cy505Cyclophosphamide 50mg/kg total dose; Bu165Busulfan 16mg/kg total dose; Bu85
Busulfan 8mg/kg total dose; Flu755Fludarabine 75mg/m
2 total dose; Flu2005Fludarabine 200mg/m
2 total dose; Clad505Cladrabine 50mg/m
2
total dose.conditioning intensity (MA versus NMA) along with
age (#45 years versus .45 years), gender, donor type
by HLA disparity (matched RD versus URD/mis-
matched RD versus UCB), CMV serostatus (donor
and recipient negative versus either positive), year of
transplant (1997-2000 versus 2001-2004), aGVHD
as a time-dependent variable, diagnosis (NHL versus
HL), and disease status at transplant (CR 11 versus
PR 11 versus minimally responsive disease defined
as less than PR but responsive to the most recent ther-
apy). Because of small numbers within each pathologicsubtype of NHL, histology was not included as a vari-
able in the comparison of outcomes after MA and
NMA conditioning. Factors were included in the
model if marginal significance (P\ .1) was noted. All
factors satisfied the proportional hazards assumptions.
RESULTS
Patient Characteristics
From 1997-2004, 141 consecutive patients with
either NHL (n 5 115) or HL (n 5 26) were treated.
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tensity (MA, n 5 65; NMA, n 5 76) are summarized
in Table 1. Significantly more NMA patients were
older, were transplanted more recently, and were
more likely to have received UCB. Similar percentages
of patients receivedmarrow grafts in each group. Of 39
patients receiving UCB, 26 patients (67%; MA, n5 2;
NMA, n5 24) received 2 UCB units. Only patients in
the NMA cohort had undergone previous AuHCT.
Older age was the predominant reason for NMA con-
ditioning (n 5 48) and the median age for patients
without prior AuHCT was 52 years (23-62 years).
Patients younger than 45 years of age (n5 28) received
NMA conditioning because of prior AuHCT (n5 17)
or extensive prior therapy (n 5 11). The median
follow-up of survivors for each cohort was similar
(MA: 39 months [range: 23-106]; NMA: 36 months
[range: 12-56]).
Survival
OS for the entire cohort at 4 years was 48% (95%
confidence interval [CI]: 39-56), with no difference be-
tween conditioning regimen intensity (4-year OS:MA:
46% [95%CI: 34-59] versus NMA: 49% [95%CI: 37-
61]; P5 .34) (Figure 1A). In univariate analysis, the use
of URD/mismatched RD compared to HLA-identical
Figure 1.Unadjusted Kaplan-Meier estimates of overall survival (A)
and progression-free survival (B) comparing myeloablative and
NMA conditioning.RD was the only significant factor, and remained sig-
nificant in multiple regression analysis (relative risk
[RR] 2.9 [95% CI 1.6-5.3, P\ .01) (Table 2). Condi-
tioning intensity, disease status at transplant, diagnosis,
and the use of UCB did not significantly impact OS.
PFS at 3 years did not differ between the MA and
NMA cohorts in either univariate or multiple regres-
sion analysis (Figure 1B and Table 2). At 3 years the
Table 2.Multivariate Analysis* for Survival, Progression-Free Survival,
and Relapse/Progression
Overall Survival
Relative Risk of
Death (95% CI) P-Value
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 0.7 (0.4-1.1) .14
Donor type
Matched related 1.0
Unrelated/mismatched related 2.9 (1.6-5.3) \.01
Umbilical cord blood 1.4 (0.8-2.6) .41
Progression-Free Survival
Relative Risk of
Death or Progression/
Relapse (95% CI) P-Value
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 0.7 (0.4-1.2) .24
Donor type
Matched related 1.0
Unrelated/mismatched related 2.4 (1.4-4.4) \.01
Umbilical cord blood 1.4 (0.8-2.4) .29
Diagnosis
NHL 1.0
Hodgkins 1.9 (1.1-3.2) .03
Disease status
CR11 1.0
PR11 0.8 (0.4-1.6) .39
Minimally responsive disease 1.9 (0.9-4.1) .09
Relapse/Progression
Relative Risk of
Relapse or Disease
Progression (95% CI) P-Value
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 3.3 (1.2-9.2) .03
Donor type
Matched related 1.0
Unrelated/mismatched related 1.1 (0.4-3.2) .88
Umbilical cord blood 2.1 (0.9-5.1) .10
CI indicates confidence interval; NHL, non-Hodgkin’s lymphoma;
CR, complete remission; PR, partial remission.
*The abovemodels are the result of multiple regression analysis after
testing the following variables: age, weight, gender, donor type,
CMV serostatus, acute GVHD (time-dependent variable), year of
transplant (1997-2000 versus 2001-2004), diagnosis, and disease
status. Conditioning intensity, as the main effect variable, is pre-
sented in every model. Otherwise, only factors with at least marginal
significance are reported.
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and NMA conditioning was 31% (95% CI: 18-49)
(P 5 .82). By univariate analysis, PFS was inferior for
patients receiving URD/mismatched RD and for pa-
tients with minimally responsive disease prior to trans-
plant. There was a trend toward inferior PFS for
patients with HL compared to NHL. In Cox regres-
sion, URD/mismatched RD and HL were associated
with significantly inferior PFS.There remained a trend
toward higher risk of death or progression for patients
with minimally responsive disease (Table 3).
The 1-year TRM was 2.5 times higher after MA
conditioning with a 1 year TRM of 43% (95% CI:
31-55) for the MA cohort and only 17% (95% CI: 9-
25) in the NMA cohort (P5 .05). In multivariate anal-
ysis, increased risk of TRM was associated with use of
an URD/mismatched RD (RR: 2.1 [1.0-4.6], P 5 .05)
and development of aGVHD $ grade II (RR: 18.4
[4.9-68.2], P\ .01). The use of NMA conditioning de-
creased the risk of TRM (RR: 0.3 [0.2-0.7], P\ .01).
Relapse and Disease Progression
NMA conditioning was associated with an in-
creased risk of relapse or disease progression at 3 years
compared to those patients receiving a MA regimen
(MA: 11% [95% CI: 3-19] versus NMA: 36% [95%
CI: 24-48], P\ .01). Other factors predictive of relapse
or disease progression by univariate analysis included
the use of UCB compared to HLA-identical matched
RD or URD/mismatched RD (42% [95% CI: 25-59]
versus 17% [95% CI: 8-26] versus 19% [95% CI:
Table 3. Multiple Regression Analysis for Acute and Chronic GVHD
(aGVHD, cGVHD)
Grade II-IV aGVHD
Relative Risk
of GVHD (95% CI) P-Value
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 1.3 (0.8-2.2) .23
Donor type
Matched related 1.0
Unrelated/
mismatched related
1.6 (0.8-2.9) .16
Umbilical cord blood 1.3 (0.7-2.2) .38
cGVHD
Relative Risk
of GVHD (95% CI) P-Value
Conditioning regimen
Myeloablative 1.0
Nonmyeloablative 2.2 (1.3-3.9) \.01
Donor type
Matched related 1.0
Unrelated/mismatched related 0.9 (0.4-1.8) .63
Umbilical cord blood 0.5 (0.3-0.9) .03
CI indicates confidence interval; GVHD, graft-versus-host disease.3-35]; P \ .01). Patients not achieving a PR or CR
immediately prior to transplant trended toward an in-
creased risk of relapse or disease progression (at 1 year:
minimally responsive disease 35% [95% CI: 16-54]
versus PR 14% [95% CI: 7-21] versus CR 21% [95%
CI: 6-36]; P 5 .08). In multiple regression analysis,
NMA conditioning and UCB donor remained as in-
creased risk factors for relapse or progression (Table 2).
Disease status at transplant was not an independent
risk factor for relapse or disease progression in the
regression model.
GVHD
The median time to onset for aGVHD grade II-IV
was slightly but not significantly longer for patients re-
ceiving NMA conditioning versus MA patients (MA:
29 days [14-73]; NMA: 35 days [14-86], P 5 .39).
The cumulative incidence of grade II-IV aGVHD at
day 100 was 51% (95%CI: 42-60) and was similar after
MA and NMA conditioning (MA: 43% [95% CI:
30-56]; NMA: 58% [95% CI: 46-70]; P 5 .47). Grade
III-IV aGVHD cumulative incidence was 20% (14-
26%) and was not statistically different between MA
(14% [95% CI: 6-22]) and NMA (25% [95% CI:
17-33]) conditioning (P 5 .26). Multiple regression
analysis found that HCT using either an URD/mis-
matched RD resulted in a 2-fold, although not signif-
icantly increased risk of grade III-IV aGVHD (RR 2.0
[95% CI: 0.7-6.2]; P 5 .21]) (Table 3). Conditioning
intensity or UCB as the stem cell source had no impact
on the incidence or severity of aGVHD.
ChronicGVHDoccurred in 46% (95%CI: 36-56)
of patients by 2 years (MA: 35% [95% CI: 22-48] ver-
sus NMA: 55% [95% CI: 41-69]; P 5 .12]). Onset of
cGVHD occurred at a median (range) of 185 days
(80-727) after MA conditioning and at 167 days
(69-514) after NMA conditioning (P 5 .47). Multiple
regression analysis (Table 3) found that NMA recipi-
ents were more than 2-fold as likely to develop
cGVHD (RR 2.2 [95% CI: 1.3-3.9]; P\ 0.01). Pa-
tients receiving UCB stem cells were significantly
less likely to develop cGVHD compared to HLA-
identical RD (RR 0.5 [95% CI: 0.3-0.9]; P 5 .03).
Engraftment
The cumulative incidence of sustained neutrophil
engraftment was 96% (95% CI: 92-99%). Neutrophil
recovery occurred at a median of 13 days (range: 0-32)
but was significantly faster in patients receiving
a NMA conditioning regimen (MA: 16 days [range,
11-31] versus NMA 10 days [0-32]; P\0.01). Platelet
engraftment by 6 months occurred in 81% (95% CI:
70-92) of patients at a median of 26 days (range:
0-134). Platelet engraftment was more rapid after
NMA conditioning (MA: 28 days [range: 16-134] ver-
sus NMA: 19 days [range; 0-69], P 5 .02).
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Thirty patients (39%) in the NMA cohort had
relapsed after a prior autologous transplant. We
analyzed the outcomes of this subset of patients in
comparison to those in the NMA cohort who had
not received a prior autologous transplant. The trans-
plant-related outcomes of relapse, TRM, PFS, and OS
were similar between patients conditioned with
a NMA regimen regardless of prior autologous trans-
plant (Table 4).
Prognostic factors Following NMA Conditioning
We performed an exploratory analysis to better
identify the patients who will experience improved
outcomes after NMA conditioning. The heterogeneity
of NHL resulted in small numbers of each pathologic
subtype although adequate patients (n5 24) with low-
grade lymphomas (follicular [FL] and small lympho-
cytic lymphoma [SLL]) were available for subgroup
analysis. Factors analyzed included histology (FL/
SLL versus HL versus other NHL), disease status at
transplant (CR versus PR versus minimally respon-
sive), stem cell source (MRD versusURD/mismatched
RD versus UCB), time from diagnosis to transplant
(#1 year versus .1-2 years versus $2 years), develop-
ment of aGVHD grade II-IV and the development of
cGVHD. Univariate analysis for PFS showed a trend
toward improved PFS at 3 years for patients with
FL/SLL (FL/SLL: 53% [95% CI: 29-77] versus HL:
20% [95% CI: 13-37] versus other NHL: 29% [95%
CI: 9-49]; P 5 .08) (Figure 2). The cumulative inci-
dence of relapse was similar regardless of histology
(FL/SLL: 36% [95% CI: 14-58] versus HL: 25%
[95% CI: 15-55] versus other NHL: 37% [95% CI:
19-55]; P 5 .9). The trend toward improved PFS in
the FL/SLL group was due primarily to lower 1-year
TRM (FL/SLL: 4% [95% CI: 0-12] versus HL: 26%
[95% CI: 8-44] versus other NHL: 20% [95% CI:
6-34]). In Cox regression analysis (Table 5), FL/SLL
had significantly decreased risk of relapse or death
compared to HL and other NHL (FLL/SLL: RR 0.4
[95% CI: 0.1-0.9] versus HL: RR 1.0 versus other
NHL: RR 0.7 [95% CI: 0.3-1.3]; P 5 .02). Similar
Table 4. Transplant Outcomes in the NMA Cohort Comparing Patients
with and without a Prior Autologous HCT (AuHCT)
Prior
AuHCT (n 5 30)
Estimate (95% CI)
No prior
AuHCT (n 5 46)
Estimate (95% CI) P-Value
3-year OS 48% (33-63) 54% (35-73) .82
3-year PFS 30% (12-51) 36% (21-50) .86
3-year relapse/
progression
28% (13-43) 40% (25-55) .35
1-year TRM 23% ( 8-38) 13% ( 3-23) .43
OS indicates overall survival; PFS, progression-free survival; TRM,
treatment-related mortality.outcomes were observed for patients either in CR or
PR, but were inferior for minimally responsive disease
(RR 2.7 [95%CI: 1.0-7.4], P5 .05). Improved survival
was noted for patients 2 or more years from diagnosis
(RR 0.3 [95% CI: 0.1-0.6], P\ .01). Neither aGVHD
nor cGVHDwere prognostic, and no factors predicted
relapse after NMA conditioning by univariate or
multivariate analysis. For the cohort of NMA patients
(n 5 12) with FL/SLL in CR or PR transplanted 2 or
more years from diagnosis, the 3-year PFS was 83%
(95% CI: 62-100).
DISCUSSION
Our analysis demonstrates similar OS and PFS
after AlloHCT following either MA or NMA condi-
tioning. Older patients, heavily pretreated patients,
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Figure 2. Unadjusted Kaplan-Meier estimates for progression-free
survival after NMA conditioning by histologic cohorts. Follicular/
small lymphocytic lymphoma (SLL) (n 5 24), Hodgkins (n 5 23),
other NHL (n 5 29).
Table 5. Multiple Regression Analysis for PFS following NMA
Conditioning
Progression-Free Survival (PFS) after NMA Conditioning
Relative Risk of
Death without
Progression/Relapse
(95% CI) P-Value
Histologic diagnosis
Hodgkins 1.0
FL/SLL 0.4 (0.1-0.9) .02
Other NHL 0.7 (0.3-1.3) .24
Disease status
CR11 1.0
PR11 1.2 (0.5-2.9) .68
Minimally responsive disease 2.7 (1.0-7.4) .05
Years from diagnosis to HCT
# year 1.0
1-\2 years 0.4 (0.2-1.2) .10
$2 years 0.3 (0.1-0.6) \.01
NHL indicates non-Hodgkin’s lymphoma; CR, complete remission;
PR, partial remission; HCT, hematopoietic cell transplants; CI,
confidence interval; FL, follicular; SLL, small lymphocytic
lymphoma.
544 M. Tomblyn et al.and patients who relapsed after a prior AuHCT com-
prised the bulk of the patients in the NMA cohort.
The reasons for failure differed with higher TRM after
MA conditioning balanced by the greater risk of
relapse after NMA conditioning. There was no impact
of prior AuHCT on outcomes. Both HLA-identical
RD and UCB grafts were suitable for either MA or
NMA transplants.
Four retrospective analyses have compared MA to
NMA conditioning for lymphoma with varied out-
comes [8-11]. In a small series (n 5 23), Bertz and
colleagues [8] found improved 1-year OS after Flu-
based NMA conditioning (67%) compared to MA
conditioning (23%, P\ .02). Rodriguez et al [9] re-
ported on 88 patients (matched RD, n 5 63; URD, n
5 25) transplanted between 1991 and 2003. The MA
and NMA cohorts were sequential as the center
changed fromMA conditioning to NMA conditioning
for lymphoma patients in 2000. Similar to our study,
they found no difference in OS and PFS at 2 years
based on conditioning intensity. An analysis of 168 pa-
tients with HL from the European Blood and Marrow
TransplantationGroup (EBMT) [11] noted a trend to-
ward improved 5-year OS after NMA conditioning
(28% [95%CI: 18-38]) compared to MA conditioning
(22% [95% CI: 13-31%]). Multivariate analysis dem-
onstrated a 2-fold relative risk of decreased survival af-
ter MA conditioning. Sorror et al. [10,20] reported
that improved OS and lower TRM is only realized in
those patients with an HCT-specific comorbidity in-
dex score of $1 receiving an NMA conditioning regi-
men (score 1-2: n 5 46; score 3: n 5 62) compared to
MA conditioning (score 1-2: n 5 18; score 3: n 5 22).
Similar to our study, all of these analyses are limited by
significant differences in patient characteristics be-
cause of selection bias for conditioning intensity based
on center specific criteria. Despite this limitation, the
data from our study and others suggest that NMA con-
ditioning in older or more heavily pretreated patients
is a reasonable therapeutic option.
The heterogeneity of histologic subtypes and dis-
ease status in lymphoma confounds outcomes assess-
ment after AlloHCT. An analysis from the EBMT
evaluated 188 lymphoma patients after NMA condi-
tioning with a short median follow-up (\1 year) [21].
The estimated 1-year OS and PFS were 62% and
46%, respectively. The EBMT study found that resis-
tant lymphoma or high grade lymphoma yielded infe-
rior PFS. They reported no effect of donor type on
transplant outcomes. In our study, only the use of
a mismatched RD/URD or a diagnosis of HL led to
decreased PFS. Within the exploratory analysis after
NMA conditioning, factors associated with improved
PFS included an indolent histology, pretransplant
CR or PR, and 2 or more years from diagnosis until
transplant. Our data, in conjunction with the EBMT
report, suggests that the graft-versus lymphoma effectmay be most potent in slow growing and responsive
disease. Our outcomes after NMA conditioning are
similar to other studies reported [22,23].
In multivariate analysis, we demonstrated a 2-fold
increased risk of cGVHD after NMA transplantation
compared to MA transplantation. This is somewhat
unexpected given that UCB transplant was associated
with a lower risk of cGVHD and the majority of
UCB recipients received NMA conditioning. Possi-
bilities include the differences in graft source, HLA
matching, and GVHD prophylaxis that were con-
founded by the main effect variable of conditioning
intensity. However, our incidence of cGVHD after
NMA conditioning is similar to other reports of
NMA conditioning for lymphoma [22,23]. We also
noted a trend toward an increased risk of relapse in
patients receiving UCB transplant. This may be corre-
lated with the 2-fold reduction in cGVHD for UCB
recipients. This suggests that there may be a correla-
tion between cGVHD and the GVL effect.
Retrospective studies comparing MA and NMA
conditioning are confounded by differences in patient
characteristics for those who receive either condition-
ing intensity. Our institutional algorithm dictates con-
ditioning intensity based upon age, extent of prior
therapy and comorbidity. The heterogeneity of the
lymphomas would require that any prospective studies
be designed to study the impact of conditioning inten-
sity with attention to specific histologic subtypes and
careful identification of patients suitable for each con-
ditioning approach. A Blood and Marrow Transplant
Clinical Trials Network (BMT CTN)-Cooperative
Intergroup Study is in development to assess the out-
comes of NMA AlloHCT in patients with Follicular
NHL, a histologic subgroup where AlloHCT has
shown promise [24,25].
We observe that similar transplant outcomes are
achieved after AlloHCT with MA conditioning in
younger patients compared to NMA conditioning in
older patients or those with prior AuHCT. Prospec-
tive trials studying NMA conditioning in specific
histologic subtypes appropriate for patient age and rel-
evant comorbidities are warranted to define the best
application of AlloHCT for NHL.
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